FDA cancels Cipla unit's drug licence: During an inspection in June, FDA officials found that the packaging of Reactin Plus Tablets, a Schedule H prescription medicine, carried an unauthorised claim describing it as an analgesic and antipyretic.
FDA cancels Cipla unit's drug licence: During an inspection in June, FDA officials found that the packaging of Reactin Plus Tablets, a Schedule H prescription medicine, carried an unauthorised claim describing it as an analgesic and antipyretic.
<iframe src="https://hindustansphere.com/embed/cluster/b44b7e22660e1cd4ea965a1bc037b8481a810c79" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Tukaram Mundhe-led Maharashtra FDA cancels Cipla unit's drug licence over Reactin Plus irregularities"></iframe>
FDA cancels Cipla unit's drug licence: During an inspection in June, FDA officials found that the packaging of Reactin Plus Tablets, a Schedule H prescription medicine, carried an unauthorised claim describing it as an analgesic and antipyretic.
